Tags

Type your tag names separated by a space and hit enter

Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia.
Front Physiol. 2021; 12:636609.FP

Abstract

Sickle cell anemia (SCA) is a hereditary hemoglobinopathy with a variable phenotype. There is no single biomarker that adequately predicts disease severity and can be used to monitor treatment response in patients in clinical trials and clinical care. The use of clinical outcomes, such as vaso-occlusive crises (VOC), requires long and expensive studies, sometimes with inconclusive results. To address these limitations, there are several biomarkers under study to improve the ability to predict complications and assess treatment response in both clinical and research settings. Oxygen gradient ektacytometry, also called as oxygenscan, is an assay that measures the effects of deoxygenation and reoxygenation on red blood cell (RBC) deformability and is gaining popularity in SCA research, because it captures the dynamic sickling capacity of a patient's RBCs as they are subjected to an oxygen gradient under steady shear stress. We describe here the oxygenscan methodology and evaluate the correlation between oxygenscan parameters and more well-known biomarkers of SCA such as fetal hemoglobin (HbF), F-cells, and dense red blood cells (DRBCs). Our data indicate that the oxygenscan curve is affected by all these parameters and the result incorporates the effects of %HbF, %F-cells, RBC hydration, and RBC membrane deformability.

Links

PMC Free PDF

Authors+Show Affiliations

Sadaf A
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Seu KG
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Thaman E
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Fessler R
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Konstantinidis DG
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Bonar HA
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Immunopathology Laboratory, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Korpik J
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Erythrocyte Diagnostic Laboratory, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Ware RE
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, United States.
McGann PT
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, United States.
Quinn CT
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Erythrocyte Diagnostic Laboratory, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, United States.
Kalfa TA
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Erythrocyte Diagnostic Laboratory, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, United States.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33841173

Citation

Sadaf, Alina, et al. "Automated Oxygen Gradient Ektacytometry: a Novel Biomarker in Sickle Cell Anemia." Frontiers in Physiology, vol. 12, 2021, p. 636609.
Sadaf A, Seu KG, Thaman E, et al. Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Front Physiol. 2021;12:636609.
Sadaf, A., Seu, K. G., Thaman, E., Fessler, R., Konstantinidis, D. G., Bonar, H. A., Korpik, J., Ware, R. E., McGann, P. T., Quinn, C. T., & Kalfa, T. A. (2021). Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology, 12, 636609. https://doi.org/10.3389/fphys.2021.636609
Sadaf A, et al. Automated Oxygen Gradient Ektacytometry: a Novel Biomarker in Sickle Cell Anemia. Front Physiol. 2021;12:636609. PubMed PMID: 33841173.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. AU - Sadaf,Alina, AU - Seu,Katie G, AU - Thaman,Elizabeth, AU - Fessler,Rose, AU - Konstantinidis,Diamantis G, AU - Bonar,Holly A, AU - Korpik,Jennifer, AU - Ware,Russell E, AU - McGann,Patrick T, AU - Quinn,Charles T, AU - Kalfa,Theodosia A, Y1 - 2021/03/25/ PY - 2020/12/01/received PY - 2021/03/05/accepted PY - 2021/4/12/entrez PY - 2021/4/13/pubmed PY - 2021/4/13/medline KW - F-cell KW - dense red blood cells KW - erythrocyte KW - fetal hemoglobin KW - oxygen gradient ektacytometry KW - oxygenscan KW - red blood cell KW - sickle cell anemia SP - 636609 EP - 636609 JF - Frontiers in physiology JO - Front Physiol VL - 12 N2 - Sickle cell anemia (SCA) is a hereditary hemoglobinopathy with a variable phenotype. There is no single biomarker that adequately predicts disease severity and can be used to monitor treatment response in patients in clinical trials and clinical care. The use of clinical outcomes, such as vaso-occlusive crises (VOC), requires long and expensive studies, sometimes with inconclusive results. To address these limitations, there are several biomarkers under study to improve the ability to predict complications and assess treatment response in both clinical and research settings. Oxygen gradient ektacytometry, also called as oxygenscan, is an assay that measures the effects of deoxygenation and reoxygenation on red blood cell (RBC) deformability and is gaining popularity in SCA research, because it captures the dynamic sickling capacity of a patient's RBCs as they are subjected to an oxygen gradient under steady shear stress. We describe here the oxygenscan methodology and evaluate the correlation between oxygenscan parameters and more well-known biomarkers of SCA such as fetal hemoglobin (HbF), F-cells, and dense red blood cells (DRBCs). Our data indicate that the oxygenscan curve is affected by all these parameters and the result incorporates the effects of %HbF, %F-cells, RBC hydration, and RBC membrane deformability. SN - 1664-042X UR - https://www.unboundmedicine.com/medline/citation/33841173/Automated_Oxygen_Gradient_Ektacytometry:_A_Novel_Biomarker_in_Sickle_Cell_Anemia_ DB - PRIME DP - Unbound Medicine ER -